Compare OIS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OIS | STTK |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 682.7M | 569.1M |
| IPO Year | 2000 | 2020 |
| Metric | OIS | STTK |
|---|---|---|
| Price | $9.92 | $7.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $14.00 | $10.00 |
| AVG Volume (30 Days) | ★ 773.0K | 460.4K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,088,133,000.00 | $1,000,000.00 |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 62.26 | N/A |
| 52 Week Low | $3.33 | $0.71 |
| 52 Week High | $14.50 | $7.68 |
| Indicator | OIS | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 31.42 | 75.24 |
| Support Level | $5.72 | $1.85 |
| Resistance Level | $11.88 | N/A |
| Average True Range (ATR) | 0.42 | 0.51 |
| MACD | -0.19 | 0.05 |
| Stochastic Oscillator | 0.24 | 86.25 |
Oil States International Inc is a provider of manufactured products and services to customers in the energy, military and industrial sectors. The company operates through three business segments - Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. Its customers include many national oil and natural gas companies, and independent oil and natural gas companies, offshore drilling companies and other oilfield service, defense and industrial companies.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.